Suitrox

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Suitrox

Property Description
Active ingredient Azithromycin
Pharmacological class Macrolide Antibacterial (Azalide)
Origin Semi-synthetic
Form Tablet, capsule, oral suspension, IV solution
General Purpose Bacterial infection control

What Type of Medicine is Suitrox?

Suitrox is a medicine whose active component is Azithromycin, classifying it as a broad-spectrum anti-infective agent used against susceptible bacteria. It belongs to the macrolide class of antibiotics, defined by its macrocyclic lactone ring structure. Azithromycin is specifically categorized as an azalide, a subclass known for unique chemical properties that contribute to its enhanced stability and long duration of action. The compound is semi-synthetic, derived from the naturally occurring macrolide, Erythromycin, but modified to optimize its performance in the human body.


The Core Component: Azithromycin's Purpose and Composition

The fundamental purpose of Suitrox is to control and resolve infections caused by susceptible bacterial pathogens. The medicine’s action is generally considered bacteriostatic, meaning it inhibits the bacteria's growth and reproduction by interfering with their ability to synthesize proteins, rather than directly destroying the cells. Clinical guidelines affirm that Azithromycin is a key therapeutic agent for addressing various bacterial pathogens, including those responsible for respiratory and skin infections. Suitrox is a single-component product, containing only the active ingredient Azithromycin, supplied alongside inactive excipients necessary for forming the dosage.


Suitrox Dosage Forms and Physical Nature

Azithromycin is manufactured in several dosage forms to accommodate various patient needs and administration routes. These preparations include forms for oral administration, such as tablets and oral suspension, as well as a form designed for intravenous solution. The availability of the oral suspension form makes it clinically recognized for treating infections in patient groups that may have difficulty swallowing solid tablets. This versatility in physical nature ensures the medicine can be delivered appropriately across different phases of care.

Regulatory References

  1. CDC Guidelines for Outpatient Antibiotic Use (Respiratory/Skin)

What side effects are possible with Suitrox?

Possible side effects and safety information

The safety profile of Suitrox (Azithromycin) is officially categorized by frequency and the physiological systems affected, as documented by regulatory agencies like the FDA and EMA.

Adverse Reaction Scope

Component Description
Most Common Events Diarrhea, nausea, abdominal pain, vomiting, and headache are frequently reported adverse reactions, typically categorized as Common (incidence ge 1%) in official labeling.
System-Organ Classes Effects are documented across the Gastrointestinal (CDAD, loose stools), Hepatobiliary (Hepatitis, Hepatic failure), and Cardiac (QT prolongation, Torsades de pointes) systems.
Serious Adverse Reactions Regulatory documents highlight rare but serious risks, including potentially fatal cardiac arrhythmias (Torsades de pointes), severe hepatic failure, and life-threatening severe cutaneous adverse reactions (SJS, DRESS).

Safety Considerations and Restrictions

Official safety information details constraints and population-specific considerations. The medicine is contraindicated in individuals with a known allergy to Azithromycin, Erythromycin, or any macrolide antibiotic. Caution is advised in patients with pre-existing QT interval prolongation, uncorrected hypokalemia/hypomagnesemia, or a history of Myasthenia Gravis due to the potential for symptom exacerbation.

Specific safety notes exist for certain groups: older adults may have increased susceptibility to cardiac events, and use in neonates has been associated with a reported risk of Infantile Hypertrophic Pyloric Stenosis (IHPS). Furthermore, the risk of acute cardiovascular death is noted to be greater during the first five days of use.

Overdose and Emergency Response

The official regulatory profile for Suitrox overdose defines the presentation primarily through severe gastrointestinal symptoms, including profound nausea, vomiting, diarrhea, and acute stomach discomfort. Additionally, the prescribing information documents that overexposure carries the potential for serious systemic outcomes. Most critically, these outcomes include prolonged cardiac repolarization which may lead to QT interval prolongation and the risk of severe ventricular arrhythmias, such as the life-threatening Torsades de pointes. Severe hepatotoxicity, including documented cases of hepatic failure, is also listed as a potential consequence of toxicity.

Due to these potential life-threatening cardiac and systemic risks, regulatory authorities explicitly mandate that individuals must seek immediate medical attention or contact a poison control center immediately for any suspected overdose. The documented procedures for managing Suitrox overdose are strictly limited to providing symptomatic therapy and general supportive measures, as the official labeling states that no specific antidote is known. The profile also highlights that individuals with pre-existing cardiac conditions are at an increased risk of severe cardiac events, and advises immediate medical consultation for infants exhibiting serious gastrointestinal symptoms.

Therapeutic Uses of Suitrox

What Suitrox treats: Main Uses and Benefits

Suitrox is generally used to help manage a wide range of bacterial infections across multiple body systems. It is applied across domains where additional symptomatic support is needed for conditions like community-acquired pneumonia, acute sinusitis, bronchitis exacerbations, acute otitis media, and certain skin infections. This medicine helps address symptom clusters that may become disruptive, such as persistent cough, fever, difficulty breathing, and localized inflammatory pain.

It also supports control of the bacterial organism in cases of uncomplicated sexually transmitted diseases (STDs) and is used as an alternative therapeutic option for patients with allergies to other common treatments. This application assists with maintaining functional stability during difficult episodes.

“The medicine contributes to improved comfort during periods of heightened symptoms, which is a supportive benefit for patients dealing with acute symptomatic discomfort.”

Quick Fact: Supports Management of Fever and Localized Pain

Regulatory References

  1. NIH MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

Suitrox (generic name: Mabsetinib) is prescribed to manage specific inflammatory and autoimmune conditions. Determining who can use Suitrox depends on the patient's medical history, current health status, and specific diagnosis. It is generally intended for adults who have not responded adequately to other standard therapies.


Who Can Use Suitrox?

Condition
Rheumatoid Arthritis (moderate to severe)
Psoriatic Arthritis
Ankylosing Spondylitis
Certain Inflammatory Bowel Diseases (e.g., severe ulcerative colitis)

Who Should Not Use Suitrox (Contraindications)?

Suitrox is contraindicated and should not be used by individuals with certain pre-existing conditions, as this could lead to serious adverse effects. Absolute contraindications include:

  • A known hypersensitivity or severe allergic reaction to Mabsetinib or any other component of the formulation.
  • Active, serious infections, including conditions like active tuberculosis (TB).
  • Active liver disease or significantly elevated liver enzymes, depending on the severity.
  • A history of untreated or uncontrolled heart failure (NYHA Class III/IV).

Healthcare providers must conduct thorough screenings before prescribing Suitrox to assess the risk of latent infections (like TB or Hepatitis B) and to evaluate the patient's cardiovascular and hepatic function.

What should I know about interactions with other medicines?

Suitrox Interactions with other medicines and products

The official regulatory profile for Suitrox (Azithromycin) defines specific restrictions and mandatory administration conditions based on documented interaction patterns.

Interaction Severity Interacting Products or Conditions
Contraindicated Ergot Alkaloids (e.g., Ergotamine) due to the established risk of ergotism; Cisapride due to the severe risk of ventricular arrhythmias and Torsades de Pointes.
Exposure Modification P-glycoprotein Substrates (e.g., Digoxin) resulting in increased serum levels; Nelfinavir increasing Azithromycin plasma concentrations.

Pharmacodynamic and Administration Constraints

Co-administration with other QT-prolonging medicines is restricted due to the combined potential for prolonged cardiac repolarization, which may lead to cardiac arrhythmia; this risk is officially noted as potentially heightened in elderly patients and women. Azithromycin may also potentiate the effects of Oral Anticoagulants (e.g., Warfarin), an interaction that requires monitoring of patient blood tests. The regulatory label documents that Azithromycin does not interact significantly with the hepatic Cytochrome P450 system.

For absorption management, Antacids containing aluminum or magnesium hydroxide must not be taken simultaneously; administration requires a separation of at least 1 hour before or 2 hours after Azithromycin. Increased systemic exposure is also observed in patients with Severe Renal Impairment.

Mechanism of Action

Inhibition of Bacterial Protein Synthesis

Suitrox (Azithromycin) primarily functions as an inhibitor by binding to the 23S rRNA component within the peptide exit tunnel of the bacterial 50S ribosomal subunit. This interaction physically obstructs the translocation process, thereby halting the elongation of polypeptide chains. The resulting suppression of microbial protein synthesis effectively prevents bacterial proliferation, a physiological consequence that facilitates the clearance of non-replicating microbial agents by host defense mechanisms.

Modulation of Host Inflammatory Signals

Beyond its core anti-infective action, the drug acts as a modulator by achieving high concentration within host immune cells like phagocytes. Intracellularly, it regulates specific inflammatory responses by suppressing key signaling pathways, such as NF-kappaB activation. This results in the reduced production of pro-inflammatory mediators, which structurally influences the progression of inflammatory tissue changes.

Mechanism Constraints and Resistance

The application of this mechanism is functionally limited by bacterial counter-mechanisms, predominantly the ribosomal modification (methylation of the 23S rRNA) and the activation of efflux pumps that actively export the drug from the cell. These resistance pathways prevent the drug's access to or binding at its target.

Dosage and Administration Information

Suitrox (Azithromycin) is officially administered via two distinct routes: Oral (using tablets or suspension forms) and Intravenous (IV) Infusion. The pattern of use is structured by short, time-limited total-dose regimens. For common adult infections, a standard 1,500 mg total course may be delivered, often as 500 mg once daily for three consecutive days or administered over a five-day sequence (500 mg on the first day, followed by 250 mg once daily for the next four days). For certain uncomplicated single-organism infections, a 1 gram single oral dose may be prescribed.

The administration is subject to specific contextual timing instructions. Standard oral tablets and suspensions can generally be taken with or without food. However, special oral formulations must be taken on an empty stomach, either one hour before or two hours after a meal. Intravenous administration, often reserved for initial therapy in severe cases, requires adherence to detailed procedural steps: the lyophilized powder must undergo reconstitution and subsequent dilution to a specified concentration before slow infusion and is strictly prohibited from being administered as an IV bolus.

Pediatric patients (under 45 kg) require dosing based on body weight (mg/kg), typically utilizing the oral suspension form. Official guidance states that patients with mild to moderate renal or hepatic impairment generally require no dose adjustment. If a dose is missed, official protocols advise taking it immediately if within 12 hours have passed, or skipping it if the delay is greater than 12 hours to maintain the intended schedule. This short-course, high-level scheduling defines the standardized, label-based approach to using the medicine.

Recent Clinical Evidence

Research evidence / Overview of studies for Suitrox

The clinical evaluation of Suitrox, whose active component is Azithromycin, is primarily based on evidence from controlled clinical trials and meta-analyses published in the peer-reviewed scientific literature. This research describes how the medicine was studied for outcomes related to patient symptoms and the pathogen status.


Evidence for Acute Respiratory and Sinus Infections

Research has extensively examined Azithromycin in conditions involving periods of heightened symptoms, such as community-acquired pneumonia (CAP) and acute exacerbations of chronic bronchitis. These were typically short-term, randomized controlled trials. Outcomes measured included measurements of success in clinical response and the ability to achieve control of the target bacteria.

Findings describe patterns observed where research examined clinical response measurements, and these were compared to the results from alternative antibiotic groups. For instance, in hospitalized patients with CAP, trials reported that the measured outcomes related to acute changes were similar to those observed in the comparator groups. Studies focused on uncomplicated skin and genital tract infections also monitored clinical resolution, with findings describing patterns of pathogen status that were observed in many trials.

Evidence for Long-Term Management and Gaps

Research also explored Azithromycin's use in chronic settings, particularly for patients with Cystic Fibrosis (CF). Long-term, placebo-controlled trials tracked changes in lung function ( FEV1) and pulmonary exacerbation frequency.

Multiple trials reported that the measured outcomes reflecting daily functioning or activity level showed patterns related to a small shift that was observed in the Azithromycin group compared to placebo over 6 months. Some trials described that the measured outcomes describing episodic or acute changes were less frequent; however, this finding was observed in some studies but not across all trials. A key area of uncertainty is the development of antimicrobial resistance, which is an area of continued research, particularly with long-term use.

Frequently Asked Questions (FAQ)

Common questions about Suitrox (FAQ)


Q: What is the main thing Suitrox is prescribed for?

A: Suitrox (Azithromycin) is officially categorized as a macrolide antibacterial drug. According to prescribing information, it is used to treat mild to moderate infections that are caused by specific susceptible bacteria. These typically include conditions affecting the respiratory system, such as community-acquired pneumonia, or infections like pharyngitis and tonsillitis.

Q: Is Suitrox the same kind of medicine as [similar common drug name]?

A: Regulatory documents classify Suitrox as a macrolide antibacterial drug. This is a specific class of antibacterial medication. The active ingredient, Azithromycin, is the basis for this classification.

Q: Does Suitrox cause weight gain or loss?

A: While weight gain is not listed as a common side effect in official documents, loss of appetite has been reported. In rare instances, and particularly in neonates, weight loss or lack of expected weight gain has been noted in association with a rare adverse event, as indicated in the official prescribing information.

Q: What are the most common side effects people report when taking Suitrox?

A: Studies and official information indicate that the most commonly reported side effects include mild gastrointestinal issues. These effects typically involve diarrhea, abdominal pain, nausea, and vomiting.

Q: Can Suitrox be taken at the same time as common pain relievers?

A: Official interaction data indicates no known direct interaction between Suitrox and a common non-steroidal anti-inflammatory drug (NSAID) like Ibuprofen. However, all medicines, including pain relievers, have independent warnings regarding their use in patients with pre-existing conditions.

Q: Do you need a prescription to get Suitrox?

A: According to official drug information sources, Suitrox (Azithromycin) is a medication that requires a prescription. It is only obtained following authorization from a healthcare provider.

Q: Why is Suitrox used for more than one condition?

A: The regulatory label for Suitrox lists its approved use for a range of mild to moderate infections. This is because the medication is effective against several different types of susceptible bacteria that can cause infections in respiratory, skin, and genitourinary areas.

Q: Can older adults (seniors) generally use Suitrox?

A: Official information indicates that, in terms of drug clearance, the process is similar in elderly men compared to young adults. However, older adults are identified as a population group with a potentially heightened risk for specific cardiac adverse effects, such as QT prolongation.

Q: Is Suitrox safe to take if I have liver problems?

A: Official prescribing information lists a history of liver disease with prior Azithromycin use as a contraindication (a reason not to use the drug). There have been reports of abnormal liver function. If signs of liver injury occur, official regulatory guidance requires the medicine to be discontinued.

Q: Is it normal to feel tired or dizzy when starting Suitrox?

A: Official safety documents list dizziness as a potential symptom associated with the serious, but rare, risk of QT prolongation. Fatigue is also noted as a symptom that may be related to potential liver problems.

Q: Is there a generic version of Suitrox available?

A: Official drug registries confirm that the active ingredient in Suitrox, Azithromycin, is available in generic form.

Q: What foods or drinks should people avoid while taking Suitrox?

A: Regulatory guidance notes that the use of alcohol is generally discouraged while taking this medication due to a potential increase in certain side effects. Additionally, antacids containing aluminum or magnesium must be taken at least 1 to 2 hours apart from Suitrox to prevent issues with drug absorption.

Q: How long does Suitrox stay in your system?

A: Studies indicate that the medicine has a long terminal half-life of 68 hours, meaning it takes time for the body to process it. Based on pharmacokinetic calculations, Suitrox is generally considered to be eliminated from the system approximately 15.5 days after the final dose.

Q: What patient groups are generally excluded from using Suitrox?

A: Official documents list several contraindications, or reasons why the drug should not be used. These exclusions include patients with a known allergy or hypersensitivity to Azithromycin or other macrolide antibiotics, as well as those with a history of cholestatic jaundice or liver dysfunction related to previous Azithromycin use.

Q: Are there different strengths or forms of Suitrox available?

A: According to official drug labels, Suitrox is available in multiple forms. These include standard oral tablets, a powder for oral suspension, and a form for intravenous (IV) injection.

Q: Does Suitrox interact with hormonal birth control?

A: Official guidance indicates that Suitrox does not directly stop hormonal contraceptives from working. However, if the medication causes severe vomiting or diarrhea, the efficacy of oral contraceptive pills may be affected, and additional precautions may be noted in the patient information.

Q: Can people who drive or operate machinery take Suitrox?

A: The regulatory label notes that the medication may be associated with central nervous system (CNS) side effects such as dizziness and, in rare instances, fainting. These potential effects may impact a person's ability to safely operate a vehicle or machinery.

Q: Is it possible to become dependent on Suitrox?

A: Official drug information sources confirm that Suitrox (Azithromycin) is an antibiotic, and it is not considered to be addictive. The medicine does not have properties that lead to drug dependence.

Q: Can I stop taking Suitrox abruptly if I feel better?

A: The official guidance for proper use advises taking the medicine only as directed by the prescriber. The full course of therapy is generally intended for the treatment to be effective.

Q: What should I do if a side effect is bothering me?

A: Official patient information advises patients to seek guidance from their prescribing healthcare provider if they have questions about their treatment. If symptoms of a serious side effect are experienced, official guidelines state that immediate medical attention is necessary.

Q: What does the box warning or Black Box Warning on Suitrox mean?

A: Official regulatory information indicates that Suitrox carries a Black Box Warning, which is a prominent warning reserved for serious potential side effects. This warning highlights the rare risk of prolonged electrical activity in the heart (QTc prolongation) and severe rhythm disturbances like Torsades de Pointes.

Q: Is Suitrox a new drug or has it been used for a long time?

A: The active ingredient in Suitrox, Azithromycin, was initially approved by the FDA in 1991. This history indicates that the medication has been used in clinical practice for a long period of time.

Q: Can Suitrox be used during pregnancy or breastfeeding?

A: The medicine is classified as Pregnancy Category B. Official guidance states that its use during pregnancy is reserved for situations where the benefit is determined to outweigh the potential risk. Small amounts of the drug are present in human milk; any decision to use it while breastfeeding is based on an assessment of the benefits of breastfeeding versus the benefits of the drug for the mother.

Q: Is Suitrox a treatment or just a way to manage symptoms?

A: Official documents describe Suitrox as an antibacterial drug. Its mechanism of action involves killing bacteria or preventing their growth, meaning its role is to treat the underlying bacterial infection rather than simply managing symptoms.

Q: Is it normal for Suitrox to cause mild stomach upset?

A: Official clinical trial data indicates that symptoms of mild stomach upset, such as nausea and abdominal pain, are listed among the most common side effects reported by patients.

Q: What should be done in the event of an overdose of Suitrox?

A: Official guidance requires immediate medical assistance, such as contacting a poison control center, in the event of a suspected overdose. Symptoms of toxicity may include severe nausea, vomiting, abdominal pain, and potential heart rhythm disturbances like QT interval prolongation.

Q: What is the difference between Suitrox and its metabolite?

A: Regulatory information regarding drug excretion indicates that Suitrox is eliminated primarily as the unchanged drug. This suggests that its breakdown products (metabolites) do not play a significant role in its active clearance from the body.

Q: Can Suitrox affect fertility?

A: In animal studies conducted on rats, the use of Azithromycin was associated with reduced pregnancy rates. However, the official regulatory label explicitly states that the relevance of this specific finding to human fertility is unknown.

Q: What evidence exists about Suitrox's use in children?

A: Official regulatory labels contain specific indications for use in children and outline pediatric dosage guidelines. Approved uses include treating conditions such as acute otitis media (for children starting at 6 months) and pharyngitis/tonsillitis (for children starting at 2 years).

Q: How does Suitrox differ from older medicines used for the same purpose?

A: Compared to some older antibiotics, Suitrox is noted for its favorable drug interaction profile because it is reported not to interact significantly with the hepatic Cytochrome P450 system. It also has a long terminal half-life of 68 hours due to its extensive distribution into body tissues.

Q: Are there any special warnings listed in the patient information for Suitrox?

A: Yes, the official documents contain warnings for several potential severe adverse events. These include QT prolongation (a change in heart rhythm), serious allergic reactions, the potential for liver injury, and a rare pediatric warning for Infantile Hypertrophic Pyloric Stenosis (IHPS) in newborns.

Q: Does Suitrox change how my body absorbs other medicines?

A: Regulatory information indicates that macrolide drugs like Suitrox can interact with the way the body handles other medicines, specifically those that are substrates for P-glycoprotein. This interaction can affect the absorption or excretion of co-administered drugs.

Q: Where can I find the official prescribing information for Suitrox?

A: The full regulatory documentation, including detailed safety and use instructions, is available in the official drug labels. Patients can typically find the official Prescribing Information by searching regulatory body websites, such as the FDA or EMA.

Q: Does Suitrox require special monitoring or blood tests?

A: Official information advises immediate discontinuation if signs of liver injury (hepatotoxicity) occur. Also, when Suitrox is taken alongside certain medicines, like Oral Anticoagulants, official guidance requires careful monitoring of patient blood tests.

How should Suitrox be stored and disposed of?

How to Store and Dispose of Suitrox?

Storage and handling requirements for Suitrox (Azithromycin) are strictly defined by the dosage form.

Storage Requirements

  • Tablets/Capsules and Dry Powder: Store below 30 C (86 F) and keep in the tightly closed, original container to protect it from moisture.
  • Reconstituted Suspension: Store at 5^circ to 30 C (41^circ to 86 F). The liquid must not be frozen.
  • Child Safety: All forms must be stored out of the reach and sight of children.

Stability and Disposal

The mixed liquid suspension is stable for only 10 days when stored correctly. Any unused suspension remaining after this period must be discarded. Disposal of expired or unused medicine must follow local regulatory guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Suitrox found in:

A-Z Index: